Bio Free Cash Flow Per Share from 2010 to 2024
| BIO-B Stock | USD 336.00 3.36 0.99% |
Free Cash Flow Per Share | First Reported 2010-12-31 | Previous Quarter 7.47245712 | Current Value 7.85 | Quarterly Volatility 5.46792023 |
Check Bio Rad financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Rad's main balance sheet or income statement drivers, such as Depreciation And Amortization of 153.2 M, Interest Expense of 51.9 M or Selling General Administrative of 475.9 M, as well as many indicators such as Price To Sales Ratio of 3.71, Dividend Yield of 0.0 or PTB Ratio of 2.15. Bio financial statements analysis is a perfect complement when working with Bio Rad Valuation or Volatility modules.
Bio | Free Cash Flow Per Share |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.